Heterocyclic sulfonamide derivative and medicine comprising same
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.
1. A compound represented by formula (I):
wherein
Q is ═O;
partial structure (b) containing ring A
is any of the groups of the following formulas:
wherein k is 0 or 1, R 6 is a cyclic C 3-6 alkyl group optionally containing a hetero atom, a halogeno group, a C 1-6 alkoxy group, a C 1-6 alkoxycarbonyl group, an amino group, an amino group mono- or di-substituted by a C 1-6 alkyl group or a hydroxy group;
X is -Cy;
Cy is any of the groups of the following formulas
partial structure (c)
is any of the groups of the following formulas
partial structure (a)
is any of the groups of the following formulas
wherein R 1 is hydrogen;
R 4 is hydrogen; and
R 5 is hydrogen,
or a pharmaceutically acceptable salt thereof.
2. The compound or pharmaceutically acceptable salt according to claim 1 , wherein the partial structure (b) containing ring A
is a group of the following formula
3. The compound or pharmaceutically acceptable salt according to claim 1 , wherein the partial structure (b) containing ring A
is a group of the following formula
4. The compound according to claim 1 , which is represented by any of the following structural formulas:
or a pharmaceutically acceptable salt of said compound.
5. A pharmaceutical composition, comprising a compound or pharmaceutically acceptable salt according to claim 4 and one or more pharmaceutically acceptable carriers.
6. A method for the treatment of a disease involving TRPA1, comprising administering an effective amount of a compound or pharmaceutically acceptable salt according to claim 4 to a subject in need thereof,
wherein said disease involving TRPA1 is chronic pain, acute pain, diabetic neuropathy, osteoarthritis, asthma, chronic coughing, chronic obstructive pulmonary disease, functional gastrointestinal disorder, reflux esophagitis, irritable bowel syndrome, inflammatory bowel disease, pancreatitis, anticancer agent-induced neuropathy, pruritus, or allergic dermatitis.
7. The method according to claim 6 , wherein said disease involving TRPA1 is chronic pain, acute pain, asthma, chronic obstructive pulmonary disease, functional gastrointestinal disorder, reflux esophagitis, inflammatory bowel disease, anticancer agent-induced neuropathy, or pruritus.
8. A pharmaceutical composition, comprising a compound or pharmaceutically acceptable salt according to claim 1 and one or more pharmaceutically acceptable carriers.
9. A method for the treatment of a disease involving TRPA1, comprising administering an effective amount of a compound or pharmaceutically acceptable salt according to claim 1 to a subject in need thereof,
wherein said disease involving TRPA1 is chronic pain, acute pain, diabetic neuropathy, osteoarthritis, asthma, chronic coughing, chronic obstructive pulmonary disease, functional gastrointestinal disorder, reflux esophagitis, irritable bowel syndrome, inflammatory bowel disease, pancreatitis, anticancer agent-induced neuropathy, pruritus, or allergic dermatitis.
10. The method according to claim 9 , wherein said disease involving TRPA1 is chronic pain, acute pain, asthma, chronic obstructive pulmonary disease, functional gastrointestinal disorder, reflux esophagitis, inflammatory bowel disease, anticancer agent-induced neuropathy, or pruritus.